

Olga Riabova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10192137/publications.pdf>

Version: 2024-02-01

28
papers

775
citations

567281

15
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

961
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning Models for <i>Mycobacterium tuberculosis</i> In Vitro Activity: Prediction and Target Visualization. <i>Molecular Pharmaceutics</i> , 2022, 19, 674-689.	4.6	8
2	A proof-of-concept study for the efficacy of dispirotriperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis. <i>Antiviral Research</i> , 2022, 202, 105327.	4.1	4
3	Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 774-781.	2.8	5
4	New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. <i>ACS Infectious Diseases</i> , 2020, 6, 313-323.	3.8	11
5	The past, present and future of RNA respiratory viruses: influenza and coronaviruses. <i>Pathogens and Disease</i> , 2020, 78, .	2.0	7
6	6,11-Dioxobenzo[<i>f</i>]pyrido[1,2- <i>a</i>]indoles Kill <i>Mycobacterium tuberculosis</i> by Targeting Iron-Sulfur Protein Rv0338c (IspQ), A Putative Redox Sensor. <i>ACS Infectious Diseases</i> , 2020, 6, 3015-3025.	3.8	9
7	Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. <i>Frontiers in Microbiology</i> , 2020, 11, 292.	3.5	5
8	Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against <i>Burkholderia cenocepacia</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 562.	3.5	5
9	<i>Mycobacterium abscessus</i> , an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5868.	4.1	84
10	Competitive Fitness of Essential Gene Knockdowns Reveals a Broad-Spectrum Antibacterial Inhibitor of the Cell Division Protein FtsZ. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	28
11	Copper-related toxicity in replicating and dormant <i>Mycobacterium tuberculosis</i> caused by 1-hydroxy-5- <i>R</i> -pyridine-2(1- <i>H</i>)-thiones. <i>Metallomics</i> , 2018, 10, 992-1002.	2.4	22
12	Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	49
13	Benzoylphenyl thiocyanates are new, effective inhibitors of the mycobacterial resuscitation promoting factor B protein. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017, 16, 69.	3.8	8
14	Antiretroviral Activity Of a Novel Pyrimidyl-Di(Diazaspiroalkane) Derivative. <i>Acta Naturae</i> , 2017, 9, 105-107.	1.7	2
15	Discovery of new diketopiperazines inhibiting <i>Burkholderia cenocepacia</i> quorum sensing in vitro and in vivo. <i>Scientific Reports</i> , 2016, 6, 32487.	3.3	46
16	Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhinovirus and Enteroviruses. <i>ChemMedChem</i> , 2015, 10, 1629-1634.	3.2	33
17	Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. <i>Antiviral Research</i> , 2015, 123, 138-145.	4.1	14
18	QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3. <i>Future Medicinal Chemistry</i> , 2011, 3, 15-27.	2.3	17

#	ARTICLE	IF	CITATIONS
19	<i>Per aspera ad astra</i>: application of Simplex QSAR approach in antiviral research. Future Medicinal Chemistry, 2010, 2, 1205-1226.	2.3	58
20	New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Research, 2009, 81, 56-63.	4.1	46
21	Transformations of 5-nitropyrimidines. Journal of Heterocyclic Chemistry, 2008, 45, 621-643.	2.6	9
22	Identification of individual structural fragments of N,N ² -(bis-5-nitropyrimidyl)dispirotriperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. Journal of Antimicrobial Chemotherapy, 2007, 60, 68-77.	3.0	41
23	Quantitative Structure-Activity Relationship Studies of [(Biphenyloxy)propyl]isoxazole Derivatives. Inhibitors of Human Rhinovirus 2 Replication. Journal of Medicinal Chemistry, 2007, 50, 4205-4213.	6.4	73
24	Synthesis and antileprosy activity of some dialkyldithiocarbamates. Journal of Antimicrobial Chemotherapy, 2006, 57, 1134-1138.	3.0	41
25	Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrzolo[1,5-a]pyrimidines and their analogs. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 37-39.	2.2	33
26	Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. Journal of Antimicrobial Chemotherapy, 2005, 56, 648-656.	3.0	48
27	Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. Journal of Antimicrobial Chemotherapy, 2005, 55, 483-488.	3.0	45
28	Synthesis, cytotoxicity and antiviral activity of N,N ² -bis-5-nitropyrimidyl derivatives of dispirotriperazine. Antiviral Research, 2002, 55, 117-127.	4.1	24